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ERLOTINIB THERAPY FOR RECURRENT RESPIRATORY PAILLOMATOSIS AND EXTRALARYNGEAL SPREAD IN PEDIATRICS

Shirley Abraham MD, John Kuttesch MD, Erica Bennett MD
Shirley Abraham MD, SMAbraham@salud.unm.edu

Background
Recurrent respiratory papillomatosis (RRP) can be a
potentially life-threatening condition and a treatment
challenge. There is currently no cure for this disease,
and treatment is primarily concerned with control of
lesions with local surgical therapies. Surgical
interventions are associated with significant scarring
and detrimental effects on patient voice and respiratory
status.
More attention is being placed on finding alternative
therapies to decrease the need for frequent surgeries.
Epidermal growth factor receptors (EGFR) have
increased expression in respiratory papillomas making
them a potential pharmacologic target. EGFR inhibitors
have been reported to be an effective adjunctive
therapy in patients with RRP

Objectives
•To report our institutional experience with Erlotinib, an
EGFR inhibitor, in two pediatric patients with severe RRP.

Methods
• Retrospective

Patient 2 is 14y/o M referred to us at age 12.
Diagnosed at 5 months with RP of the larynx. Underwent
micro-laryngoscopy, bronchoscopy with laser or surgical
excision of the lesions, on a 1-2 monthly basis. He
developed respiratory distress post laryngoscopy and
found to have 3 pulmonary lesions confirmed as
papillomatosis post thoracotomy with wedge resections.

Discussion
In our two patient cohort, a regimen of erlotinib and DIM
resulted in decreased disease burden and an increase
in intervals for required MLB and surgical excisions. In
both patients studied. Both patients tolerated this
therapy regimen well with minimal dermatologic and
gastrointestinal side effects. Of note, it is interesting that
patient 2 had an EGFR negative biopsy sample while
having positive outcomes on treatment. The sample in
question was from a metastatic site other than the
primary laryngeal site. Positive results could be for a
number of reasons including primary site expression of
EGFR or unknown down-stream effects of erlotinib as
described by Ishii et al in EGFR negative non small cell
3
lung cancer. Our sample size described was small and
a larger population is needed to study this treatment
regimen against a control to better understand the
possible potential benefits versus surgical excision as
monotherapy.

•Both patients were started on an EGFR inhibitor,
Erlotinib at a dose of 85mg/m2 daily and DIM
(diindolylmethane) 150mg twice daily. The skin care
regimen included regular moisturizers and sunscreen;
topical steroids and antibiotics as needed. Therapy was
well tolerated except for grade 1 skin rash in both
patients and grade 1 diarrhea as well, in Patient 1.
•For patient 1, within a month of therapy there was
significant decrease in the lesions and by 6mo complete
resolution of papillomatosis. She had 15mo of therapy.
She is in remission 6 years off therapy. For patient 2,
there has been decrease in lesions and the interval
between laryngoscopy since start of therapy. CTs of
chest confirm no recurrence of pulmonary lesions since
starting Erlotinib.
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•Patient 1 is a 19y/o F referred to us at age 11.Diagnosed
with RRP at birth. Since age 1.5yrs, underwent microlaryngoscopy, bronchoscopy with laser or surgical excision
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bronchus. Biopsy of the lesion showed squamous
papilloma, EGFR positive.
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